An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.

ABSTRACT:

Background and objective

Over the past 5 years, adjuvant treatment options for surgically resected stage III melanoma have expanded with the introduction of several novel immune checkpoint inhibitors and targeted therapies. Pembrolizumab, a programmed cell death protein 1 inhibitor, received US Food and Drug Administration approval in 2019 for resected high-risk stage III melanoma based on significantly longer recurrence-free survival versus placebo. This study evaluated the cost-effectiveness of pembrolizumab versus other adjuvant treatment strategies for resected high-risk stage III melanoma from a US health system perspective.

Methods

A Markov cohort-level model with four states (recurrence-free, locoregional recurrence, distant metastases, death) estimated costs and qual

SUBMITTER: Bensimon AG 

PROVIDER: S-EPMC7311503 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature